NY

Nyxoah SABRU Nyxoah Stock Report

Last reporting period 30 Jun, 2024

Updated 16 Oct, 2024

Last price

Market cap $B

0.467

Micro

Exchange

XBRU - Euronext Brussels

NYXH.BR Stock Analysis

NY

Uncovered

Nyxoah SA is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-21/100

Low score

Market cap $B

0.467

Dividend yield

Shares outstanding

25.846 B

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 106 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

View Section: Eyestock Rating